ArticleCancer communications (London, England)2018
Cancer mortality in Serbia, 1991-2015: an age-period-cohort and joinpoint regression analysis.
Article in Cancer communications (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Hepatitis B in China: the analysis of mortality and burden of disease trends from 2008 to 2021.BMC public health · 2026Article
- COPD in China: the analysis of mortality and burden of disease trends from 2008 to 2021.Respiratory research · 2026Article
- Multidimensional analysis of pulmonary tuberculosis epidemiological characteristics in Jining City from 2010 to 2024: an integrated study based on spatial clustering, trend regression, and age-period-cohort modeling.Frontiers in public health · 2026Article
- Trends in incidence and mortality of lung cancer and age-period-cohort model analysis in Zibo, Shandong Province, 2014-2024.Frontiers in oncology · 2026Article
- Burden and Trends of Aortic Aneurysms in Individuals Aged 55 and Older from 1990 to 2021: A Systematic Analysis of the Global Burden of Disease Study 2021.Global heart · 2026Article
- Pancreatic cancer in China: the analysis of cancer mortality and burden in China, 2008-2021.BMC cancer · 2025Article
- Global trends, age-period-cohort analysis, and future projections of diarrhea burden: Findings from the Global Burden of Disease Study 2021.Biosafety and health · 2025Article
- Spatial-Temporal Trends of Cancer Among Women in Central Serbia, 1999-2021: Implications for Disaster and Public Health Preparedness.Healthcare (Basel, Switzerland) · 2025Article
- Predicting Pre- and Post-Diagnostic Depression in Women with Abnormal Pap Screening Tests: A Neural Network Approach.Life (Basel, Switzerland) · 2025Article
- The Burden and Trends of Gynecological Cancers in Asia from 1980 to 2021, with Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021.Current oncology (Toronto, Ont.) · 2025Article
- The global burden of heart failure attributable to interstitial lung diseases: insights from the global burden of disease study 2021.BMC cardiovascular disorders · 2025Article
- Epidemiological trends in gastrointestinal cancers and risk factors across U.S. states from 2000 to 2021: a systematic analysis for the global burden of disease study 2021.BMC public health · 2025Article
- Article
- Validity of the process and outcome specific measure in women with abnormal Papanicolaou screening test.PloS one · 2025Article
- Update on the global burden of acute viral hepatitis in 2021: addressing health inequalities.Frontiers in public health · 2025Article
- Application and Challenge of Metalloporphyrin Sensitizers in Noninvasive Dynamic Tumor Therapy.Molecules (Basel, Switzerland) · 2024Review
- Two Decades of Progress in Personalized Medicine of Colorectal Cancer in Serbia-Insights from the Institute for Oncology and Radiology of Serbia.Biomedicines · 2024Article
- An Artificial Neural Network Prediction Model of Depressive Symptoms among Women with Abnormal Papanicolaou Smear Results before and after Diagnostic Procedures.Life (Basel, Switzerland) · 2024Article
- Article
- Incidence Trends, Clinicopathologic Characteristics, and Overall Survival Prediction in Retinoblastoma Children: SEER Prognostic Nomogram Analysis.The oncologist · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the result of dramatic political changes, civil wars, and a long-term refugee crisis from the end of the last to beginning of this century, the population of Serbia has experienced significant health problems. The aim of this study was to assess cancer mortality trends in Serbia.
methodsThis nationwide study was carried out to analyze cancer mortality in Serbia during 1991-2015 using official data. The age-standardized mortality rates (per 100,000) were calculated by direct standardization, using the world standard population by Segi. The average annual percent change (AAPC) and corresponding 95% confidence interval (CI) were computed using joinpoint regression analysis. Age-period-cohort analysis was performed to address the possible underlying reasons for the observed temporal trends.
resultsOver the 25-year study period, there were 466,075 cancer deaths (266,043 males and 200,032 females) in Serbia. Overall cancer mortality increased between 1991 and 2009 in both males (by + 0.9% per year) and females (by + 0.8% per year) and has been decreasing since then, by - 0.9% annually in both sexes. For almost all major cancers except stomach cancer, cancer mortality in Serbia demonstrated upward trends during the study period. The largest increases were noted in lung cancer among females (AAPC = + 3.7, 95% CI 3.5-3.9) and prostate cancer in males (AAPC = + 1.9, 95% CI 1.4-2.3).
conclusionsAfter two decades of increase, cancer mortality rates are finally declining in Serbia. Despite this, these rates place Serbia among the countries with the highest cancer mortality in the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.